Unresolving trismus following third molar surgery: Report of a case of fibrodysplasia ossificans progressiva with review of literature

References

• Altschuler EL. Consideration of Rituximab for fibrodysplasia ossificans progressiva. Med Hypotheses. 2004;63:407–408.10.1016/j.mehy.2004.04.024
   PubMed Web of Science ®Google Scholar
• Culbert AL, Chakkalakal SA, Convente MR, et al. Fibrodysplasia (myositis) ossificans progressiva. In: Thakker RV, Whyte MP, Eisman JA, et al., editors. Genetics of bone biology and skeletal disease. New York (NY): Elsevier; 2013. p. 375–396.10.1016/B978-0-12-387829-8.00024-X
   Google Scholar
• Sendur OF, Gulcan G. Severe limitation in jaw movement in a patient with fibrodysplasia ossificans progressiva: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:312–317.10.1016/j.tripleo.2005.09.020
   PubMed Web of Science ®Google Scholar
• Carvalho DR, Farage L, Martins BJAF, et al. Craniofacial findings in fibrodysplasia ossificans progressiva: computerized tomography evaluation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;111:499–502.10.1016/j.tripleo.2010.12.002
   PubMed Web of Science ®Google Scholar
• Takayuki A, Hiroyuki N, et al. Myositis ossificans traumatica of the masticatory muscles: review of the literature and report of a case. J Oral Maxillofac Surg. 2002;60:1083–1088.
   PubMed Web of Science ®Google Scholar
• Orhan K, Uyanık LO, et al. Unusually severe limitation of the jaw attributable to fibrodysplasia ossificans progressiva: a case report with cone-beam computed tomography findings. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:404–409.10.1016/j.tripleo.2011.03.011
   PubMed Web of Science ®Google Scholar
• Kaplan FS, Chakkalakal SA, Shore EM. Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis. Dis Model Mech. 2012;5:756–762.10.1242/dmm.010280
   PubMed Web of Science ®Google Scholar
• Morales-Piga A, Bachiller-Corral J, Trujillo-Tiebas MJ, et al. Fibrodysplasia ossificans progressiva in Spain: epidemiological, clinical, and genetic aspects. Bone. 2012;51:748–755.10.1016/j.bone.2012.07.002
   PubMed Web of Science ®Google Scholar
• Kaplan FS, Groppe J, Shore EM. When one skeleton is enough: approaches and strategies for the treatment of fibrodysplasia ossificans progressiva (FOP). Drug Discov Today Ther Strateg. 2008;5:255–262.10.1016/j.ddstr.2008.11.004
   PubMedGoogle Scholar
• Gebara NV, Heller GD, Phillips CD, et al. MR findings of fibrodysplasia ossificans progressiva complicated by acute cord compression: Case report and literature review. Radiol Case Rep. 2011;6:467.10.2484/rcr.v6i4.467
   PubMedGoogle Scholar
• Leavitt D, Teeples J, Viozzi CF. Submandibular space swelling in a patient with fibrodysplasia ossificans progressiva: A diagnostic dilemma. J Oral Maxillofac Surg. 2009;67:668–673.10.1016/j.joms.2008.07.011
   PubMed Web of Science ®Google Scholar
• Bridges AJ, Hsu KC, Singh A, et al. Fibrodysplasia (Myositis) Ossificans Progressiva. Semin Arthritis Rheum. 1994;24:155–164.10.1016/0049-0172(94)90071-X
   PubMed Web of Science ®Google Scholar
• Kaplan FS, Merrer ML, Glaser DL, et al. Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol. 2008;22:191–205.10.1016/j.berh.2007.11.007
   PubMed Web of Science ®Google Scholar
• Hughes A, Monsell F, Gargan M. Fibrodysplasia ossificans progressiva. Current Orthop. 2008;22:48–51.10.1016/j.cuor.2008.01.001
   Google Scholar
• Glaser DL, Economides AN, Wang L, et al. In vivo somatic cell gene transfer of an engineered Noggin mutein prevents BMP4-induced heterotopic ossification. J Bone Joint Surg Am. 2003;85:2332–2342.10.2106/00004623-200312000-00010
   PubMedGoogle Scholar
• Kaplan FS, Glaser DL, Pignolo RJ, et al. A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton. Expert Opin Biol Ther. 2007b;7:705–712.10.1517/14712598.7.5.705
   PubMed Web of Science ®Google Scholar
• Yu PB, Deng DY, Lai CS, et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med. 2008;14:1363–1369.10.1038/nm.1888
   PubMed Web of Science ®Google Scholar
• Hong CC, Yu PB. Applications of small molecule BMP inhibitors in physiology and disease. Cytokine Growth Factor Rev. 2009;20:409–418.10.1016/j.cytogfr.2009.10.021
   PubMed Web of Science ®Google Scholar
• Kaplan J, Kaplan FS, Shore EM. Restoration of normal BMP signaling levels and osteogenic differentiation in FOP mesenchymal progenitor cells by mutant allele-specific targeting. Gene Ther. 2012;19:786–790.10.1038/gt.2011.152
   PubMed Web of Science ®Google Scholar
• Kan L, Lounev VY, Pignolo RJ, et al. Substance P signaling mediates BMP dependent heterotopic ossification. J Cell Biochem. 2011;112:2759–2772.10.1002/jcb.23259
   PubMed Web of Science ®Google Scholar
• Salisbury E, Rodenberg E, Sonnet C, et al. Sensory nerve induced inflammation contributes to heterotopic ossification. J Cell Biochem. 2011;112:2748–2758.10.1002/jcb.23225
   PubMed Web of Science ®Google Scholar
• Zasloff MA, Rocke DM, Crofford LJ, et al. Treatment of patients who have fibrodysplasia ossificans progressiva with isotretinoin. Clin Orthop Relat Res. 1998;346:121–129.
   Google Scholar
• Shimono K, Tung WE, Macolino C, et al. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor agonists. Nat Med. 2011;17:454–460.10.1038/nm.2334
   PubMed Web of Science ®Google Scholar
• Kaplan FS, Shore EM. Derailing heterotopic ossification and RARing to go. Nat Med. 2011;17:420–421.10.1038/nm0411-420
   PubMed Web of Science ®Google Scholar
• Kaplan FS, Lounev VY, Wang H, et al. Fibrodysplasia ossificans progressiva: a blueprint for metamorphosis. Ann NY Acad Sci. 2011;1237:5–10.10.1111/nyas.2011.1237.issue-1
   PubMed Web of Science ®Google Scholar
• Morales-Piga A, Javier F, Corral B, et al. Is “Fibrodysplasia Ossificans Progressiva” a vascular disease? A ground breaking pathogenic model. Reumatol Clin. 2014;10(6):389–395.10.1016/j.reuma.2014.05.001
   PubMedGoogle Scholar
• Roberts T, Stephen L, Scott C, et al. Fibrodysplasia ossificans progressiva (FOP) in South Africa: dental implications in 5 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;112:11–18.10.1016/j.tripleo.2011.03.015
   PubMed Web of Science ®Google Scholar